XJPX
2160
Market cap1.31bUSD
Oct 09, Last price
3,200.00JPY
1D
1.59%
1Q
22.84%
Jan 2017
340.37%
IPO
1,085.19%
Name
GNI Group Ltd
Chart & performance
P/E
—
P/S
7.85
EPS
—
Div yield, %
—
Shrs. gr., 5y
3.18%
Rev. gr., 5y
22.39%
Revenues
26.84b
+13.67%
Net income
-4.41b
L
CFO
-2.41b
L-23.90%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
GNI Group Ltd. is a global biopharmaceutical enterprise dedicated to the research, development, manufacturing, and commercialization of both modern pharmaceuticals and traditional Chinese medicines. The company's lead product, Etuary, is currently available for the treatment of idiopathic pulmonary fibrosis. Beyond this, Etuary is undergoing further clinical evaluation: it is in Phase III trials for connective tissue disease-associated interstitial lung disease, and in Phase II along with a pre-Phase III pilot study for radiation pneumonitis. Investigations are also underway for its application in diabetic nephropathy. GNI Group Ltd.'s pipeline additionally features F351, which is in Phase II development for liver fibrosis; F573, an early-stage compound in pre-clinical testing for acute-on-chronic liver failure; and Tamibarotene, intended for the treatment of acute promyelocytic leukemia. Established in 2001, the company's headquarters are located in Tokyo, Japan.
Related entities
Subsidiaries (2)
AYUMI Pharmaceutical Holdings KK
AYUMI Pharmaceutical Corporation
Key people
Tomoya Kitagawa
Chief Financial Officer, Executive Officer, Director · since 2024
Executive Officer, Director · since 2025
Takuya Kaneko
Executive Officer, Chief Strategy Officer · since 2025
Kazuhiro Kawachi
Executive Officer, Chief Business Development Officer
Tracy Mu
Executive Officer, Director of Finance and Accounting, Manager of President's Office · since 2024
Thomas Eastling
Director · since 2022
Ying Luo
Executive President, Chief Executive Officer, Representative Executive Officer, Chairman of Subsidiaries, Director · since 2021
Ryosuke Matsui
Executive Vice President, Chief Financial Officer, Chief Operating Officer, Director · since 2025
Kanako Kikuchi
Independent Director · since 2023
Masahiro Matsuoka
Independent Director · since 2025
Hideaki Sashiwa
Independent Director · since 2008
Headquarters & legal address
日本橋本町二丁目2番2号
東京都 中央区 103-0023
JP
東京都 中央区 103-0023
JP
Address
2-2-2, Nihonbashi-Honcho
Chuo-ku Tokyo 103-0023
JP
Chuo-ku Tokyo 103-0023
JP
Address
2-2-2, Nihonbashi Honcho
Chuo-ku Tokyo 103-0023
JP
Chuo-ku Tokyo 103-0023
JP
Other language
GNI Group Ltd.
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||